Skip to main content

Table 2 Overall and subgroup meta-analysis of the association between SNHG20 expression and OS

From: Prognostic and clinicopathological significance of SNHG20 in human cancers: a meta-analysis

Subgroup Studies/N Patient/N Pooled HR (95% CI) P value Heterogeneity
I2 P value Model
Overall 15 1187 2.47 (2.05, 2.98) 0.000 0.00% 0.718 Fixed-effect
Cancer type
Digestive system cancer 5 483 2.91 (2.16, 3.92) 0.000 0.00% 0.726 Fixed-effect
Osteosarcoma 2 172 1.95 (1.23, 3.09) 0.005 0.00% 0.973 Fixed-effect
Respiratory system cancer 1 42 3.78 (1.18, 12.09) 0.025
Reproductive system cancer 2 153 2.16 (0.95, 4.87) 0.065 0.00% 0.390 Fixed-effect
Head and neck cancer 3 151 1.97 (1.36, 2.85) 0.000 0.00% 0.722 Fixed-effect
Glioma 2 186 3.27 (1.84, 5.82) 0.000 50.00% 0.157 Fixed-effect
Sample size
>100 4 499 2.86 (2.09, 3.92) 0.000 39.10% 0.177 Fixed-effect
80–100 3 269 2.64 (1.81, 3.87) 0.000 0.00% 0.605 Fixed-effect
<80 8 419 2.09 (1.56, 2.81) 0.000 0.00% 0.929 Fixed-effect
Extracted method
Direct 5 539 2.55 (1.98, 3.29) 0.000 36.70% 0.176 Fixed-effect
Indirect 10 648 2.38 (1.80, 3.14) 0.000 0.00% 0.903 Fixed-effect
  1. OS Overall survival, HR hazard ratio, 95% CI 95% confidence interval